Cost-Effectiveness Analysis of Erenumab Versus OnabotulinumtoxinA for Patients with Chronic Migraine Attacks in Greece

被引：0
|
作者：
Theodoros V. Giannouchos
Dimos-Dimitrios Mitsikostas
Robert L. Ohsfeldt
Athanassios Vozikis
Paraskevi Koufopoulou
机构：
[1] Texas A&M University,Department of Health Policy and Management, School of Public Health
[2] Texas A&M University,Population Informatics Lab
[3] National and Kapodistrian University of Athens,First Neurology Department, Aeginition Hospital, School of Medicine
[4] University of Piraeus,Laboratory of Health Economics and Management, Economics Department
[5] KAT General Hospital of Attica,undefined
来源：
Clinical Drug Investigation | 2019年 / 39卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：979 / 990
页数：11
相关论文
共 50 条
  • [41] OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales
    Nick Freemantle
    Kristin Khalaf
    Clara Loveman
    Sanja Stanisic
    Dmitry Gultyaev
    Johanna Lister
    Marcus Drake
    The European Journal of Health Economics, 2016, 17 : 911 - 921
  • [42] Cost of fremanezumab, erenumab, galcanezumab and onabotulinumtoxinA associated adverse events, for migraine prophylaxis in Spain
    Irimia, Pablo
    Santos-Lasaosa, Sonia
    Garcia Bujalance, Laura
    Ramos Pinazo, Luis
    Rubio-Rodriguez, Dario
    Rubio-Terres, Carlos
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (02) : 285 - 297
  • [43] COST-UTILITY ANALYSIS OF EPTINEZUMAB VERSUS ERENUMAB FOR EPISODIC MIGRAINE HEADACHES PATIENTS IN THE UNITED STATES
    Dong, W.
    Bounthavong, M.
    VALUE IN HEALTH, 2024, 27 (06) : S113 - S113
  • [44] Cost-effectiveness analysis of formoterol versus salmeterol in patients with asthma
    Rutten-van Mölken, MPMH
    van Doorslaer, EKA
    Till, MD
    PHARMACOECONOMICS, 1998, 14 (06) : 671 - 684
  • [45] Cost-Effectiveness Analysis of Formoterol Versus Salmeterol in Patients with Asthma
    Maureen P. M. H. Rutten-van Mölken
    Eddy K. A. van Doorslaer
    M. Denise Till
    PharmacoEconomics, 1998, 14 : 671 - 684
  • [46] Cost-Effectiveness Analysis of Allopurinol Versus Febuxostat in Chronic Gout Patients: A US Payer Perspective
    Gandhi, Pranav K.
    Gentry, William M.
    Ma, Qinli
    Bottorff, Michael B.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2015, 21 (02): : 165 - 175
  • [47] Effect of Erenumab on Monthly Migraine Days and Monthly Migraine Attacks in Patients With Episodic Migraine
    Tfelt-Hansen, P.
    Ashina, M.
    Diener, H.
    Ritter, S.
    Lima, Paiva da Silva G.
    Rasmussen, S.
    Zielman, R.
    HEADACHE, 2020, 60 : 103 - 103
  • [48] Dual therapy with Erenumab and onabotulinumtoxinA: No synergistic effect in chronic migraine: A retrospective cohort study
    Jaimes, Alex
    Gomez, Andrea
    Pajares, Olga
    Rodriguez-Vico, Jaime
    PAIN PRACTICE, 2023, 23 (04) : 349 - 358
  • [49] Updated cost-effectiveness analysis of onabotulinumtoxinA for the prevention of headache in adults with chronic migraine who have previously received three or more preventive treatments in the UK
    Hollier-Hann, Georgia
    Curry, Alistair
    Onishchenko, Kateryna
    Akehurst, Ron
    Ahmed, Fayyaz
    Davies, Brendan
    Keyzor, Ian
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (01) : 113 - 123
  • [50] A Cost-Effectiveness and Budget Impact Analysis of AbobotulinumtoxinA in Greece
    Nomikos, Nikolaos
    Eleftheriou, Christos
    Athanasakis, Kostas
    TOXINS, 2023, 15 (09)
12345